GeneDx Holding Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 1,300

Employees

  • Stock Symbol
  • WGS

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $45.34
  • (As of Friday Closing)

GeneDx Holding General Information

Description

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Contact Information

Website
www.genedx.com
Formerly Known As
Mount Sinai Genomics, Sema4 Holdings, CM Life Sciences
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 333 Ludlow Street
  • North Tower, 6th floor
  • Stamford, CT 06902
  • United States
+1 (888)
Primary Industry
Other Healthcare Technology Systems
Other Industries
Drug Discovery
Stock Exchange
NAS
Corporate Office
  • 333 Ludlow Street
  • North Tower, 6th floor
  • Stamford, CT 06902
  • United States
+1 (888)

GeneDx Holding Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GeneDx Holding Stock Performance

As of 20-Nov-2026, GeneDx Holding’s stock price is $45.34. Its current market cap is $1.36B with 30M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$45.34 $49.19 $32.21 - $170.87 $1.36B 30M 865K -$3.76

GeneDx Holding Financials Summary

As of 30-Sep-2026, GeneDx Holding has a trailing 12-month revenue of $461M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 2,191,024 3,717,413 2,111,093 30,701
Revenue 460,784 427,539 305,450 202,566
EBITDA (79,708) 6,626 (27,644) (144,073)
Net Income (111,049) (21,021) (52,286) (175,767)
Total Assets 526,484 523,710 419,380 418,756
Total Debt 215,384 113,168 117,379 119,273
Public Fundamental Data provided by Morningstar, Inc. disclaimer

GeneDx Holding Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore GeneDx Holding‘s full profile, request access.

Request a free trial

GeneDx Holding Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore GeneDx Holding‘s full profile, request access.

Request a free trial

GeneDx Holding Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneer
Other Healthcare Technology Systems
Stamford, CT
1,300 As of 2025

San Francisco, CA
 

Austin, TX
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

GeneDx Holding Competitors (19)

One of GeneDx Holding’s 19 competitors is Invitae, a Formerly VC-backed company based in San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Invitae Formerly VC-backed San Francisco, CA
Natera Formerly VC-backed Austin, TX
MedGenome Labs Venture Capital-Backed Bangalore, India
Adaptive Biotechnologies Formerly VC-backed Seattle, WA
Admera Health Venture Capital-Backed South Plainfield, NJ
You’re viewing 5 of 19 competitors. Get the full list »

GeneDx Holding Patents

GeneDx Holding Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260234715-A1 Methods and systems for modeling inference of mutation impact Pending 11-Feb-2025
WO-2026173905-A1 Methods and systems for modeling inference of mutation impact Pending 11-Feb-2025
US-20260098301-A1 Methods and systems for processing genetic variations and phenotypes Pending 08-Oct-2024
WO-2026080446-A1 Methods and systems for processing genetic variations and phenotypes Pending 08-Oct-2024
US-20260057139-A1 Methods and systems for phenotypic fit analysis Pending 23-Aug-2024 G16B30/00
To view GeneDx Holding’s complete patent history, request access »

GeneDx Holding Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GeneDx Holding Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore GeneDx Holding‘s full profile, request access.

Request a free trial

GeneDx Holding Investments & Acquisitions (3)

GeneDx Holding’s most recent deal was a Merger/Acquisition with Fabric Genomics for . The deal was made on 05-May-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Fabric Genomics 05-May-2025 Merger/Acquisition Enterprise Systems (Healthcare)
CM Life Sciences 22-Jul-2021 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
Detect Genomix 12-Aug-2020 Joint Venture Biotechnology
To view GeneDx Holding’s complete investments and acquisitions history, request access »

GeneDx Holding ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

26.72 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Healthcare

Industry

of 590

Rank

Percentile

Medical Services

Subindustry

of 97

Rank

Percentile

To view GeneDx Holding’s complete esg history, request access »

GeneDx Holding Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Fabric Genomics Oakland, CA 2009

GeneDx Holding FAQs

  • When was GeneDx Holding founded?

    GeneDx Holding was founded in 2000.

  • Where is GeneDx Holding headquartered?

    GeneDx Holding is headquartered in Stamford, CT.

  • What is the size of GeneDx Holding?

    GeneDx Holding has 1,300 total employees.

  • What industry is GeneDx Holding in?

    GeneDx Holding’s primary industry is Other Healthcare Technology Systems.

  • Is GeneDx Holding a private or public company?

    GeneDx Holding is a Public company.

  • What is GeneDx Holding’s stock symbol?

    The ticker symbol for GeneDx Holding is WGS.

  • What is the current stock price of GeneDx Holding?

    As of 20-Nov-2026 the stock price of GeneDx Holding is $45.34.

  • What is the current market cap of GeneDx Holding?

    The current market capitalization of GeneDx Holding is $1.36B.

  • What is GeneDx Holding’s current revenue?

    The trailing twelve month revenue for GeneDx Holding is $461M.

  • Who are GeneDx Holding’s competitors?

    Invitae, Natera, MedGenome Labs, Adaptive Biotechnologies, and Admera Health are some of the 19 competitors of GeneDx Holding.

  • What is GeneDx Holding’s annual earnings per share (EPS)?

    GeneDx Holding’s EPS for 12 months was -$3.76.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process